{
  "id": 133,
  "language": "english",
  "hallucination": "no",
  "ground_truth_source": "text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Colleagues",
      "inferred_vibe": "Enthusiastic and Informative"
    },
    "dialogue_turns": [
      {
        "speaker": "Host_A",
        "text": "Alright, so today, we're diving into something pretty incredible â€“ the human immune system. You know, that amazing, uh, internal defense force?",
        "tts_text": "Alright, so today, we're diving into something pretty incredible - the human immune system. You know, that amazing, uh, internal defense force?",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, it's wild, right? Every time you get hit with a bug, your body just, like, figures out how to fight it. And these tiny little cells, antibodies, they're the ones doing the heavy lifting.",
        "tts_text": "Yeah, it's wild, right? Every time you get hit with a bug, your body just, like, figures out how to fight it. And these tiny little cells, antibodies, they're the ones doing the heavy lifting.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Every time youre infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Exactly! And we're talking about, um, a guy named Carl Hansen, who's totally geeking out about this. He actually exclaims, and I quote, \"We can make 100 trillion different antibodies! The immune system is spectacular beyond description.\"",
        "tts_text": "Exactly! And we're talking about, um, a guy named Carl Hansen, who's totally geeking out about this. He actually exclaims, and I quote, \"We can make one hundred trillion different antibodies! The immune system is spectacular beyond description.\"",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "We can make 100 trillion different antibodies, he exclaims. The immune system is spectacular beyond description.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "A hundred *trillion*? Wow. That sounds more like a college professor than, you know, the CEO of a multi-billion dollar biotech company.",
        "tts_text": "A hundred trillion? Wow. That sounds more like a college professor than, you know, the C E O of a multi-billion dollar biotech company.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, theres a reason: Hansen was one...",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Well, that's because he *was* a college professor! Until 2019, when he left academia to focus on AbCellera Biologics, a company he co-founded back in 2012 with fellow researchers from the University of British Columbia.",
        "tts_text": "Well, that's because he was a college professor! Until twenty nineteen, when he left academia to focus on AbCellera Biologics, a company he co-founded back in twenty twelve with fellow researchers from the University of British Columbia.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "So, um, universities are great for, like, testing ideas, right? But most biotech startups, they usually pick a few drug targets, then spend years, sometimes a decade, trying to develop those drugs. And less than ten percent actually make it to market.",
        "tts_text": "So, um, universities are great for, like, testing ideas, right? But most biotech startups, they usually pick a few drug targets, then spend years, sometimes a decade, trying to develop those drugs. And less than ten percent actually make it to market.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Nearly all biotech startups develop a handful of treatment targets, then spend the next eight to 12 years developing those drugs, hoping to bring at least one of them to market. Its not a sure thingfewer than 10% of new drugs make it all the way.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "[interrupts] Which is crazy! But when they *do* hit, they're blockbusters. Think Humira, Keytruda. Those are antibody treatments, too. But AbCellera, they do things differently.",
        "tts_text": "Which is crazy! But when they do hit, they're blockbusters. Think Humira, Keytruda. Those are antibody treatments, too. But AbCellera, they do things differently.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Seven of the 10 top-selling drugs in 2018 were antibody treatments, including AbbVies $19 billion (net revenue) immunosuppressive drug Humira and Mercks cancer drug Keytruda, which generated $11.1 billion in 2019.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, they're not trying to, like, build a whole vertically integrated drug company themselves. They just focus on the earliest, most essential part: the *discovery* process. It's almost like \"drug discovery as a service.\"",
        "tts_text": "Yeah, they're not trying to, like, build a whole vertically integrated drug company themselves. They just focus on the earliest, most essential part: the discovery process. It's almost like drug discovery as a service.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Instead of trying to build a vertically integrated drug company, it is focused solely on the discovery process. ... Instead it offers what might be described as drug discovery as a service.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Right! They work with, um, ninety outside businesses, including giants like Pfizer, Gilead, Novartis. These companies come to AbCellera and say, \"Hey, find us some antibodies for X,\" and AbCellera uses their tech to find the prospects.",
        "tts_text": "Right! They work with, um, ninety outside businesses, including giants like Pfizer, Gilead, Novartis. These companies come to AbCellera and say, \"Hey, find us some antibodies for X,\" and AbCellera uses their tech to find the prospects.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis. Those companies ask the biotech to find antibodies that meet certain criteria. AbCellera then uses its proprietary technology to find prospects.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "And their biggest success story to date? COVID-19. They, uh, examined thousands of antibodies from people who'd recovered from the virus.",
        "tts_text": "And their biggest success story to date? C O V I D-nineteen. They, uh, examined thousands of antibodies from people who'd recovered from the virus.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "And then they turned the most promising ones over to Eli Lilly. Get this: clinical trials for one of them, bamlanivimab, started just 90 days after the partnership began!",
        "tts_text": "And then they turned the most promising ones over to Eli Lilly. Get this: clinical trials for one of them, bamlanivimab, started just ninety days after the partnership began!",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "It then turned over the most promising antibodies to drug company Eli Lilly. Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "90 days! That's just wild. And it eventually got emergency-use authorization from the FDA, right? The government bought, like, 950,000 doses for over a billion dollars.",
        "tts_text": "ninety days! That's just wild. And it eventually got emergency-use authorization from the F D A, right? The government bought, like, nine hundred fifty thousand doses for over a billion dollars.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA. The federal government has contracted to purchase 950,000 doses of the drug for $1.2 billion.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Yeah, and Eli Lilly's expecting up to two billion in revenue just from COVID therapeutics in 2021, with AbCellera getting an estimated 270 million in royalties. It really shows how their model saves time and money.",
        "tts_text": "Yeah, and Eli Lilly's expecting up to two billion in revenue just from C O V I D therapeutics in twenty twenty one, with AbCellera getting an estimated two hundred seventy million in royalties. It really shows how their model saves time and money.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Eli Lilly issued guidance in mid-December expecting up to $2 billion in revenue from Covid-19 therapeutics in 2021, the bulk of which will come from bamlanivimab; AbCellera, which booked $25 million through the end of September 2020, will earn estimated royalties of $270 million on those sales, according to Credit Suisse.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Totally. Every year you shave off development, that's, like, huge savings and quicker revenue. And Hansen, um, he's now worth three billion dollars after the company's IPO.",
        "tts_text": "Totally. Every year you shave off development, that's, like, huge savings and quicker revenue. And Hansen, um, he's now worth three billion dollars after the company's I P O.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "From a financial perspective, every year that you save is a huge opportunity cost for investors, says Gal Munda, an analyst at Berenberg Capital Markets. Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "He describes it as \"a little bit surreal.\" But he says the COVID success really proves their business model and technology. Pretty impressive, huh?",
        "tts_text": "He describes it as a little bit surreal. But he says the C O V I D success really proves their business model and technology. Pretty impressive, huh?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Asked about his meteoric rise into the three-comma club, Hansen is low-key: It feels just a little bit surreal. Hes more articulate about the biotechs success: If this example of Covid shows one thing, to me, its the proof point of the business model and the technology.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Absolutely. A true game-changer in drug development.",
        "tts_text": "Absolutely. A true game-changer in drug development.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      }
    ]
  }
}